EGFR and adenocarcinoma: We then performed subgroup Kaplan-Meier analyses using only data from patients who had 1) ECOG status 0 or 1, 2) adenocarcinoma histology, 3) TKI-sensitizing EGFR mutations, 4) gefitinib and/or erlotinib treatment or 5) first-line treatment with TKIs (Supplementary Table 4).